Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.85 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.85 |
| ▸ | ESR1 | P03372 | 5/20 | 0.78 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.78 |
| ▸ | PGR | P06401 | 2/20 | 0.78 |
| ▸ | AR | P10275 | 2/20 | 0.78 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.78 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.78 |
| ▸ | ATM | Q13315 | 2/20 | 0.78 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.78 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.78 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.78 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.78 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.78 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.78 |
| ▸ | STS | P08842 | 2/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.77 |
| ▸ | TSHR | P16473 | 2/20 | 0.76 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.76 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Estradiol Methyl Ether SCHEMBL8998255 | 0.92 | HSD17B10 (1.00) | LMNAHSD17B10ESR1SMN1; SMN2PGR | |
| SCHEMBL5078078 | 0.92 | LMNA (0.83) | LMNAHSD17B10ESR1SMN1; SMN2PGR | |
| Estradiol Methyl Ether SCHEMBL9558220 | 0.92 | HSD17B10 (1.00) | LMNAHSD17B10ESR1SMN1; SMN2PGR | |
| Estradiol Methyl Ether SCHEMBL18686406 | 0.92 | HSD17B10 (1.00) | LMNAHSD17B10ESR1SMN1; SMN2PGR | |
| Estradiol Methyl Ether SCHEMBL6464173 | 0.92 | HSD17B10 (1.00) | LMNAHSD17B10ESR1SMN1; SMN2PGR | |
| Estradiol Methyl Ether SCHEMBL23645792 | 0.92 | HSD17B10 (1.00) | LMNAHSD17B10ESR1SMN1; SMN2PGR | |
| Estradiol Methyl Ether SCHEMBL4750578 | 0.92 | HSD17B10 (1.00) | LMNAHSD17B10ESR1SMN1; SMN2PGR | |
| Estradiol Methyl Ether SCHEMBL547265 | 0.92 | HSD17B10 (1.00) | LMNAHSD17B10ESR1SMN1; SMN2PGR | |
| SCHEMBL936065 | 0.92 | LMNA (0.83) | LMNAHSD17B10ESR1SMN1; SMN2PGR | |
| Estradiol Methyl Ether SCHEMBL12593628 | 0.92 | HSD17B10 (1.00) | LMNAHSD17B10ESR1SMN1; SMN2PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1406633-B1 | ENHANCED DRUG DELIVERY IN TRANSDERMAL SYSTEMS | NOVEN PHARMA (US) | 2011-10-05 | — | — | EP | claimed |
| US-7867986-B2 | Enhanced drug delivery in transdermal systems | NOVEN PHARMACEUTICALS, INC. (US) | 2011-01-11 | — | — | US | claimed |
| CN-100391462-C | Enhanced drug delivery in transdermal systems | NOVEN PHARMA (US) | 2008-06-04 | — | — | CN | claimed |
| EP-1265617-B1 | NOVEL TOPICAL OESTROPROGESTATIONAL COMPOSITIONS WITH SYSTEMIC EFFECT | THERAMEX SAM LAB (MC) | 2006-06-21 | — | — | EP | claimed |
| US-7030104-B2 | Topical oestroprogestational compositions with a systemic effect | LABORATOIRE THERAMEX (MC) | 2006-04-18 | — | — | US | claimed |
| US-20040043943-A1 | Method for the management of incontinence | ALZA CORPORATION | 2004-03-04 | — | — | US | claimed |
| US-20040037881-A1 | Method for the management of incontinence | ALZA CORPORATION | 2004-02-26 | — | — | US | claimed |
| US-20030181430-A1 | Novel topical oestroprogestational compositions with a systemic effect | LABORATOIRE THERAMEX (MC) | 2003-09-25 | — | — | US | claimed |
| CN-1407898-A | Novel topical oestroprogestational compositions with systemic effect | THERAMEX (MC) | 2003-04-02 | — | — | CN | claimed |
| US-6262115-B1 | ADMITTING ORALLY INTO THE PATIENT A DOSAGE FORM OF OXYBUTYNIN AND ITS PHARMACEUTICALLY ACCEPTABLE SALT, THAT IS ADMINISTERED ONCE-A-DAY AS SUSTAINED-RELEASE FORM FOR MANAGEMENT OF INCONTINENCE | ALZA COPORATION | 2001-07-17 | — | — | US | claimed |
| US-20010005728-A1 | Method for the management of incontinence | ALZA CORPORATION | 2001-06-28 | — | — | US | claimed |
| CN-113480588-A | Preparation method of estradiol mesilate | 南雄阳普医疗科技有限公司 | 2021-10-08 | — | — | CN | disclosed |
| CN-111602041-A | Temperature detection ink, method for initializing temperature detection ink, temperature indicator, and article management system | 株式会社日立产机系统 | 2020-08-28 | — | — | CN | disclosed |
| EP-1406633-B1 | ENHANCED DRUG DELIVERY IN TRANSDERMAL SYSTEMS | NOVEN PHARMA (US) | 2011-10-05 | — | — | EP | disclosed |
| US-20080021102-A1 | Method for the Management of Incontinence | ALZA CORPORATION (US) | 2008-01-24 | — | — | US | disclosed |
| US-5098714-A | OSMOTIC, ORAL DOSAGE FORM FOR FERTILITY CONTROL | ALZA CORPORATION (US) | 1992-03-24 | — | — | US | disclosed |
| EP-0472645-A1 | OSMOTIC DOSAGE FORM. | ALZA CORP (US) | 1992-03-04 | — | — | EP | disclosed |
| WO-1991007173-A1 | OSMOTIC, ORAL DOSAGE FORM FOR FERTILITY CONTROL | ALZA CORPORATION (US) | 1991-05-30 | — | — | WO | disclosed |
| WO-1990014075-A1 | OSMOTIC DOSAGE FORM | ALZA CORPORATION (US) | 1990-11-29 | — | — | WO | disclosed |
| US-4948593-A | SUSTAINED AND CONTROLLED CONTRACEPTION | ALZA CORPORATION (US) | 1990-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181430-A1 | Novel topical oestroprogestational compositions with a systemic effect | CYP19A1, PGR, SHBG | LMNA 1665/4885HSD17B10 285/4885ESR1 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.